Investor Presentaiton slide image

Investor Presentaiton

3Q22 Business Results Income Statement Revenue Steady growth continued in RemsimaⓇ SC and all other products in Europe & the growth market led sound earnings, partially offset sales reduction in North America OP : Achieved solid operating profit mainly driven by stable prescription & COGS improvement of the high-margin products such as InflectraⓇ and RemsimaⓇ SC NP : Jumped by 238.9% YoY and 251.9% QoQ respectively as a result of the increase in non-operating profit due to weak Won (KRW bn) '21.3Q '22.2Q '22.3Q % YoY %QoQ Revenue 409.1 519.0 496.4 21.3% -4.4% Gross Profit 74.7 140.9 153.1 105.0% 8.7% (%) 18.3% 27.1% 30.8% 12.5%p 3.7%p SG&A 52.7 66.8 80.6 52.9% 20.7% (%) 12.9% 12.9% 16.2% 3.3%p 3.3%p Personnel expenses 12.1 13.7 14.1 16.5% 2.9% Research expenses 5.5 0.8 0.3 -94.5% -62.5% Advertising expenses 3.0 6.6 7.7 156.7% 16.7% Commissions 14.9 24.3 33.1 122.1% 36.2% Operating Profit 22.0 74.1 72.5 229.5% -2.2% (%) 5.4% 14.3% 14.6% 9.2%p 0.3%p EBIT 52.5 95.2 185.2 252.8% 94.5% Net Profit 40.6 39.1 137.6 238.9% 251.9% Investor Relations 2022 4
View entire presentation